Результаты поиска

Pulsed-dose-rate peri-operative brachytherapy as an interstitial boost in organ-sparing treatment of breast cancer.

PURPOSE: To evaluate peri-operative multicatheter interstitial pulsed-dose-rate brachytherapy (PDR-BT) with an intra-operative catheter placement to boost the tumor excision site in breast cancer patients treated conservatively. MATERIAL AND METHODS: Between May 2002 and October 2008, 96 consecutive T1-3N0-2M0 breast cancer patients underwent breast-conserving therapy (BCT) including peri-operative PDR-BT boost, followed by whole breast external beam radiotherapy (WBRT). The BT dose of 15 Gy (1 Gy/pulse/h) was given on the following day after surgery. RESULTS: No increased bleeding or delaye

Совпадение в полном тексте источника
… Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, et al. , and CASTOR Investigators. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016; 375:754–66. 10.1056/NEJMoa1606038. 20. …

Health and aging in elderly farmers: the AMI cohort.

BackgroundThe health of the agricultural population has been previously explored, particularly in relation to the farming exposures and among professionally active individuals. However, few studies specifically focused on health and aging among elders retired from agriculture. Yet, this population faces the long-term effects of occupational exposures and multiple difficulties related to living and aging in rural area (limited access to shops, services, and practitioners). However, these difficulties may be counter-balanced by advantages related to healthier lifestyle, richer social support and

Совпадение в полном тексте источника
… Qi V, Phillips SP, Hopman WM. Determinants of a healthy lifestyle and use of preventive screening in Canada. BMC Public Health. 2006;6:275. doi: 10.1186/1471-2458-6-275. Racine EF, Laditka SB, Dmochowski J, Alavanja MCR, Lee DC, Hoppin JA. …

BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting.

The BCL-2 family of proteins plays a central role in the regulation of apoptosis, with BCL-2 and BCL-xL representing two of its most prominent antiapoptotic members. This review explores the molecular regulation of BCL-2 and BCL-xL genes, emphasizing the structural domains that define the functions of the broader BCL-2 family. Beyond their canonical roles in preventing mitochondrial outer membrane permeabilization, both proteins contribute significantly to cancer development. Their overexpression enhances invasiveness and tumor progression, supports angiogenesis, and critically modulates cellu

Biomimetic materials for medical applications.

AbstractRecent advances in biomedical research have facilitated the exploration of biomimetic materials and their potential for diagnosing and treating diseases. This review synthesizes reports of recent research into biomimetic materials and provides a focused analysis of their therapeutic and diagnostic efficacy across multiple physiological systems, including the locomotor, digestive, respiratory, urinary, endocrine, nervous, integumentary, hematopoietic, and circulatory systems. These findings highlight the transformative potential of these materials in the management of systemic diseases.

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers.

Cancer is a serious disease with an increasing number of reported cases and high mortality worldwide. Gastrointestinal cancer defines a group of cancers in the digestive system, e.g., liver cancer, colorectal cancer, and gastric cancer. Coptidis Rhizoma (C. Rhizoma; Huanglian, in Chinese) is a classical Chinese medicinal botanical drug for the treatment of gastrointestinal disorders and has been shown to have a wide variety of pharmacological activity, including antifungal, antivirus, anticancer, antidiabetic, hypoglycemic, and cardioprotective effects. Recent studies on C. Rhizoma present sig

Совпадение в полном тексте источника
… Palmatine has been reported to have anticancer effects in CRC, HCC, pancreatic cancer, oral squamous cell carcinoma, breast cancer, ovarian cancer, and prostate cancer both in vitro and in vivo ( Long et al., 2019 ; Qi et al., 2019 ). …

Integrated Engineering of CAR-T Cells for Solid Tumours.

Chimeric antigen receptor (CAR) T-cell therapy has achieved durable efficacy in hematologic malignancies but encounters persistent obstacles in solid tumours, including antigen heterogeneity, a suppressive tumour microenvironment (TME), and intrinsic T-cell dysfunction. This review examines the transition from single-axis engineering to an integrated framework that addresses these hurdles in sequence. We delineate how next-generation CAR-T cells are designed for precise spatiotemporal activation through logic-gated and pharmacologically regulatable receptors, while being reinforced by metaboli

Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal.

Breast cancer remains a leading cause of cancer-related morbidity and mortality among women worldwide. Its treatment is complicated by molecular heterogeneity and the frequent development of multidrug resistance (MDR). Conventional drug delivery approaches are often limited by poor aqueous solubility, rapid systemic clearance, non-specific biodistribution, and off-target toxicity. This review will critically explore the possibility of surfactant-based drug delivery systems (DDSs) in addressing the constraints of standard breast cancer treatments. It focuses on the mechanisms by which surfactan

Cutaneous Skin Toxicities of Oncological Targeted Therapies: Comprehensive Overview of Mechanisms, Management, and Research Gaps-A Narrative Review.

Targeted therapies in oncology have become a mainstay in therapy of numerous types of cancers. They work by targeting and utilizing (activating, inhibiting, or modulating) molecular pathways that are crucial in pathogenesis of certain cancers and can be divided into numerous classes according to their mechanism. However, since the antigens and molecules they target can take part in homeostasis of the skin and the integument, cutaneous toxicities are a common occurrence. The frequency of certain cutaneous adverse events (CAEs) depends on the causal drug and varies even between drugs of the same

Совпадение в полном тексте источника
… Dan H Jiang Q Jia X Qi G Zong D Li Z Dermatologic toxicities in epidermal growth factor receptor: a comprehensive pharmacovigilance study from 2013 to 2023 Front Med 2024 10.3389/fmed.2023.1283807 PMC10848916 38327269 Dan H, Jiang Q, Jia X, Qi G, Zong D, Li Z. …

Unlocking the Therapeutic Potential of Algae-Derived Compounds in Hematological Malignancies.

Algae are a rich source of bioactive compounds that have a wide range of beneficial effects on human health and can show significant potential in the treatment of hematological malignancies such as leukemia, lymphoma, and multiple myeloma. These diseases often pose a therapeutic challenge despite recent advances in treatment (e.g., the use of immunomodulatory drugs, proteasome inhibitors, CD38 monoclonal antibodies, stem cell transplant, and targeted therapy). A considerable number of patients experience relapses or resistance to the applied therapies. Algal compounds, alone or in combination

Совпадение в полном тексте источника
… Qi Y. Li Y. Li W. Lu Z. Rao J. Engineered Algae: A Novel Oxygen-Generating System for Effective Treatment of Hypoxic Cancer Sci. Adv. 2020 6 eaba5996 10.1126/sciadv.aba5996 32490207 PMC7239646 30. Sreenikethanam A. Raj S. Gugulothu P. Bajhaiya A.K. … Qi Y. Xie T. Qiao Y. Zhou M. Calcium Phosphate Engineered Photosynthetic Microalgae to Combat Hypoxic-Tumor by in-Situ Modulating Hypoxia and Cascade Radio-Phototherapy Theranostics 2021 11 3580 3594 10.7150/thno.55441 33664849 PMC7914342 137. Xin Z. Zhang M. Cui H. Ding X. Zhang T. Wu L. Cui H. …

Unraveling the Potential of SGK1 in Osteoporosis: From Molecular Mechanisms to Therapeutic Targets.

Osteoporosis (OP) is a prevalent metabolic bone disease, with several million cases of fractures resulting from osteoporosis worldwide each year. This phenomenon contributes to a substantial increase in direct medical expenditures and poses a considerable socioeconomic burden. Despite its prevalence, our understanding of the underlying mechanisms remains limited. Recent studies have demonstrated the involvement of serum glucocorticoid-regulated protein kinase 1 (SGK1) in multiple signaling pathways that regulate bone metabolism and its significant role in the development of osteoporosis. There

Совпадение в полном тексте источника
… Wang S., Deng Z., Ma Y., Jin J., Qi F., Li S., Liu C., Lyu F.J., Zheng Q. The Role of Autophagy and Mitophagy in Bone Metabolic Disorders. Int. J. Biol. Sci. 2020;16:2675–2691. doi: 10.7150/ijbs.46627. 107. Young A.R.J., Cassidy L.D., Narita M. …

Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias.

Chimeric antigen receptor (CAR) cellular therapies have advanced outcomes in challenging hematologic malignancies like leukemia, lymphoma, and multiple myeloma. Plasma cell-directed CAR T-cell therapies have been particularly beneficial in multiple myeloma, suggesting that these agents may have a role in other challenging plasma cell disorders such as systemic AL amyloidosis and plasma cell leukemia. AL amyloidosis is a monoclonal plasma cell disorder resulting in the deposition of protein fibrils that compromise end-organ function. Delays in diagnosis can result in end-organ dysfunction and o

Совпадение в полном тексте источника
… Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. (2022) 28:1189–98. doi: 10.1038/s41591-022-01800-8 10. Botta GP, Chao J, Ma H, Hahn M, Sierra G, Jia J, et al. … Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res. (2020) 26:3979–89. doi: 10.1158/1078-0432.CCR-19-3259 14. …

Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies.

Several novel T-cell-based therapies have recently become available for multiple myeloma (MM). These T-cell redirecting therapies (TRTs) include chimeric antigen receptor T-cells (CAR-T) and bispecific antibodies (BiAbs). In both clinical trial and real-world data, these therapies have demonstrated high rates of deep clinical response, and some are now approved for second-line treatment for relapsed MM. The deep and sustained clinical responses these therapies are capable of inducing will require sophisticated response monitoring to provide meaningful information for patient care. Obtaining me

Совпадение в полном тексте источника
… Qi M. Krevvata M. Lin T.S. Khare V. … Qi K. Londhe A. Nair S. Lin X. Pei L. Comparative Efficacy of Teclistamab Versus Physician’s Choice of Therapy in the Long-Term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma Clin. …

Recent Trends in anti-tumor mechanisms and molecular targets of celastrol.

Celastrol, a compound derived from traditional Chinese medicine, has therapeutic effects and has been used to treat inflammation-related diseases, cancer, cardiovascular diseases, and neurodegenerative diseases. However, current reviews lack a comprehensive and systematic summary of the anti-tumor mechanisms and molecular targets of celastrol. For this reason, this paper reviews the anticancer properties of celastrol and the molecular mechanisms underlying its anticancer effects. This paper primarily focuses on the mechanism of action of celastrol in terms of inhibition of cell proliferation a

Совпадение в полном тексте источника
… Zhang W, Wu Z, Qi H, Chen L, Wang T, Mao X. et al. Celastrol upregulated ATG7 triggers autophagy via targeting Nur77 in colorectal cancer. Phytomedicine. 2022;104:154280. doi: 10.1016/j.phymed.2022.154280. 48. Zhang CJ, Zhu N, Long J, Wu HT, Wang YX, Liu BY. et al. … Qi S, Deng S, Lian Z, Yu K. Novel Drugs with High Efficacy against Tumor Angiogenesis. Int J Mol Sci. 2022;23:6934. doi: 10.3390/ijms23136934. 82. Al-Ostoot FH, Salah S, Khamees HA, Khanum SA. Tumor angiogenesis: Current challenges and therapeutic opportunities. …

Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma.

Therapy for multiple myeloma (MM), a hematologic neoplasm of plasma cells, has undergone remarkable changes over the past 25 years. Small molecules (molecular weight of less than one kDa), together with newer immunotherapies that include monoclonal antibodies, antibody-drug conjugates, and most recently, chimeric antigen receptor (CAR) T-cells, have combined to double the disease's five-year survival rate to over 50% during the past few decades. Despite these advances, the disease is still considered incurable, and its treatment continues to pose substantial challenges, since therapeutic refra

Совпадение в полном тексте источника
… Qi J. Hajek R. Facon T. Rosinol L. Williams C. Blacklock H. Goldschmidt H. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double-blind study Lancet Oncol. 2013 14 1129 1140 10.1016/S1470-2045(13)70398-X 24055414 70. … Qi J. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 2011 146 903 916 10.1016/j.cell.2011.08.017 PMC3187920 21889194 91. Jung M. Gelato K.A. Fernandez-Montalvan A. Siegel S. Haendler B. …

Novel Therapeutics for Anthracycline Induced Cardiotoxicity.

Anthracyclines remain an essential component of the treatment of many hematologic and solid organ malignancies, but has important implications on cardiovascular disease. Anthracycline induced cardiotoxicity (AIC) ranges from asymptomatic LV dysfunction to highly morbid end- stage heart failure. As cancer survivorship improves, the detection and treatment of AIC becomes more crucial to improve patient outcomes. Current treatment modalities for AIC have been largely extrapolated from treatment of conventional heart failure, but developing effective therapies specific to AIC is an area of growing

Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation.

A quarter-century after the discovery of autotaxin in cell culture, the autotaxin-lysophosphatidate (LPA)-lipid phosphate phosphatase axis is now a promising clinical target for treating chronic inflammatory conditions, mitigating fibrosis progression, and improving the efficacy of existing cancer chemotherapies and radiotherapy. Nearly half of the literature on this axis has been published during the last five years. In cancer biology, LPA signaling is increasingly being recognized as a central mediator of the progression of chronic inflammation in the establishment of a tumor microenvironmen

Совпадение в полном тексте источника
… Qi R. Leung P.S. Bowlus C.L. Gershwin M.E. Autotaxin, pruritus and primary biliary cholangitis (PBC) Autoimmun. Rev. 2016 15 795 800 10.1016/j.autrev.2016.03.019 27019050 126. Ikeda H. Yatomi Y. Autotaxin in liver fibrosis Clin. Chim. …

Объединение АИ, вакцин РНК и ЦАР-Т ячеек для индивидуального лечения.

Онкология претерпевает глубокие преобразования, вызванные конвергенцией искусственного интеллекта (AI), вакцин на основе РНК и химерика антигенного рецептора Т-клеток (CAR-T). В индивидуальном порядке эти технологии позволяют диагностировать рак, лечить и стратифицировать пациента. Подходы, основанные на принципе АИ, способствуют обнаружению наркотиков, оптимизации клинических опытных разработок и создают возможности для индивидуализированного терапевтического принятия решений. Вакцины RNA обеспечивают гибкую платформу для кодирования неонантигенов опухоли, в то время как CAR-T-терапия дает во

Совпадение в полном тексте источника
… S. , Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment , Journal of Clinical Medicine . ( 2024 ) 13 , no. 21, 10.3390/jcm13216537 , 6537 . 39518676 PMC11546714 35 Fu R. , Qi R. , and Xiong H. , et al. …

GMrepo v3: кустарная база данных о кишечном микробиоме человека с расширенным охватом заболеваний и усовершенствованным биомаркером с перекрестными данными.

GMrepo (Gut Microbiome Data Repository) представляет собой кустарную и последовательно аннотированную базу данных по метагеномам человеческого кишечника, предназначенную для повышения возможности повторного использования данных и создания возможностей для межпроектных и перекрестных сопоставлений. В этом последнем выпуске GMrepo v3 был расширен до 890 проектов и 118 965 пробегов/выборок, включая 87 048 16S rRNA и 31 917 метагеномических наборов данных. Количество аннотированных заболеваний возросло со 133 до 302, что позволило провести более комплексный микробиомический анализ, связанный с заб

Совпадение в полном тексте источника
… Shi W, Qi H, Sun Qet al. gcMeta: a global catalogue of metagenomics platform to support the archiving, standardization and analysis of microbiome data. Nucleic Acids Res. 2019;47:D637–48. 10.1093/nar/gky1008. 30. Gonzalez A, Navas-Molina JA, Kosciolek Tet al. …

Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Significance of Pre-Transplant Controlling Nutritional Status Score.

Nutritional status is an important prognostic factor in patients with multiple myeloma (MM). The Controlling Nutritional Status (CONUT) score has shown promise in predicting outcomes in various malignancies; however, its role in autologous stem cell transplantation (ASCT) in patients with MM remains unclear. This study aimed to evaluate the significance of pre-transplant CONUT scores in predicting post-transplant engraftment kinetics and early complications in patients with MM undergoing ASCT. This single-center, retrospective study analyzed 59 multiple myeloma patients who underwent ASCT betw

Совпадение в полном тексте источника
… Liang F., Dong X.Y., Tang G.F., Qi K.M., Chen W., Sang W., Sun H.Y., Cao J., Cheng H., Li D.P., et al. Influence of prognostic nutritional index and controlling nutritional status on the prognosis of patients with multiple myeloma. …

Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experience.

Multiple myeloma (MM) is a malignancy characterized by the clonal proliferation of plasma cells. It accounts for approximately 1% of all cancers and is the second most common hematologic malignancy after lymphoma. Infections represent a major cause of morbidity and mortality in patients with newly diagnosed multiple myeloma (NDMM), contributing to approximately 45% of early deaths, particularly in elderly individuals and during the initial months of therapy. Current treatment options for MM, including anti-CD38 monoclonal antibodies (CD38 mAbs), proteasome inhibitors, immunomodulatory drugs (s

Совпадение в полном тексте источника
… Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL,Krevvata M, Chiu C, Qin X, Okonkwo L, Trivedi S, Ukropec J, Qi M, Miguel JS(2020) Daratumumab Plus Lenalidomide Dexamethasone relapsed/refractory Multiple Myeloma: Ext follow-up POLLUX Randomized …